38 results about "Nucleic acid methods" patented technology

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

The invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein / antibody based therapeutics.

Methods for treating biological samples containing nucleic acids using high ionic strength and temperature. The sample may be separated into two or more phases to segregate various components of the sample for enzymatic reactions to detect sequences of interest. Kits for performing the method of the invention are also provided.

Methods of detecting at least one analyte and at least one nucleic acid in a sample are provided. Reagents for carrying out the methods are also provided.

Methods and compositions for method of generating a population of captured target nucleic acids are provided. Exemplary methods can include contacting the plurality of oligonucleotides individually linked to a solid support with a sample comprising target nucleic acids having 3' ends and 5' ends, wherein target nucleic acids anneal to some of the free 3' ends of the oligonucleotides, and wherein there is an excess of oligonucleotides such that at least some oligonucleotides remain with free 3' ends; and then extending the target nucleic acid 3' end with a polymerase using the oligonucleotide as a template to form double-stranded portions that comprise a restriction enzyme recognition sequence; and then cleaving the restriction enzyme recognition sequence with a restriction enzyme to form released target nucleic acids having a single-stranded 5' end and a double-stranded 3' end and leaving oligonucleotides remain with free 3' ends uncleaved from the solid support; and optionally then separating the solid support and uncleaved oligonucleotides from the released target nucleic acids to form a solution of target nucleic acids.

The present invention relates to a peptide with a length of 25 amino acids or less comprising the sequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (SEQ ID No: 1) as well as to A peptide with a length of 25 amino acids or less comprising the sequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (SEQ ID No: 2). The present invention further relates to a nanostructure comprising a nucleic acid scaffold and at least two peptide moieties, wherein the sequence of each of the at least two peptide moieties is independently selected from the sequence of the peptide of the invention as well as pharmaceutical compositions, nucleic acids, methods and uses related thereto.

Methods for treating biological samples containing nucleic acids using high ionic strength and high temperatures. The sample can be separated into two or more phases to isolate various components in the sample, and an enzymatic reaction is performed to detect a sequence of interest. Kits for performing the methods of the invention are also provided.

Disclosed are polypeptides useful in the treatment of diseases associated with pathogenic genomic repetitive sequences, such as neurological diseases. Nucleic acid molecules and vectors encoding such polypeptides are also disclosed. Also disclosed are therapeutic uses and methods of treating such diseases; in particular, the present invention relates to therapeutic uses and methods for the treatment of Friedel's Ataxia (FRDA). Also disclosed are methods and related peptides and nucleic acids for active, long-term delivery of therapeutic molecules to target cells in vivo or in vitro.

Methods and systems provided herein address current limitations of bisulfite-based methylation sequencing by improving the quality and accuracy of nucleic acid methylation sequencing and uses thereof for detection of disease. Methods that include minimally-destructive conversion methods for methylation sequencing as well as specialized UMI adapters provide for improved quality of sequencing libraries and sequencing information. Greater accuracy and more complete methylation-state information permits higher quality feature generation for use in machine learning models and classifier generation.

Methods and systems provided herein address current limitations of bisulfite-based methylation sequencing by improving the quality and accuracy of nucleic acid methylation sequencing and uses thereof for detection of disease. Methods that include minimally-destructive conversion methods for methylation sequencing as well as specialized UMI adapters provide for improved quality of sequencing libraries and sequencing information. Greater accuracy and more complete methylation-state information permits higher quality feature generation for use in machine learning models and classifier generation.

The invention discloses a method for rapidly detecting nucleic acid of three imported bee disease pathogens through microchip integration, and relates to the technical field of pathogen detection. The method comprises the following steps: S1, acquiring DNA of a to-be-detected bee sample; s2, respectively preparing nucleic acid amplification reaction systems of EFB, AFB and CDB pathogens, wherein each system contains an exclusive primer probe and the same basic component; s3, loading the three detection systems, the negative control and the positive control to different reaction units of the same microchip; s4, executing fluorescent quantitative PCR amplification; and S5, judging the existence of pathogens according to the detection signal. According to the invention, the limitation of cross-type pathogen detection of bacteria and fungi is broken through, single synchronous detection is realized, the time is shortened, the cost of reagent consumables is reduced by more than 80% by a 1.2 mu L small system, and the kit is strong in specificity, high in sensitivity and good in repeatability, is adaptive to a conventional PCR instrument, and assists entry quarantine and bee disease prevention and control.

Disclosed herein are polypeptides for use in treating diseases associated with pathogenic genomic repeat sequences, such as neurological disorders. Also disclosed are nucleic acid molecules and vectors that encode such polypeptides. Therapeutic uses and methods for treating such diseases are also disclosed; in particular, therapeutic uses and methods for treating Friedreich's ataxia (FRDA). Also disclosed is a method and associated peptides and nucleic acids for active, long-term delivery of therapeutic molecules to target cells in vivo or in vitro.

Disclosed herein are methods and compositions for enhancing delivery and function of vaccine components, immunotherapy Agents, and improved delivery of nucleic acid nanostructures, nucleic acids, peptides, polypeptides, and other types of cargoes. These methods and compositions utilize design components suitable for rapid and cost-effective manufacturing, and are designed to exclusively use the process of self-assembly to form nanotherapeutics requiring no purification in many instances.

Methods of detecting and optionally quantifying cancer nucleic acid in patient samples. The methods can include identifying one or more structural variants in cancer nucleic acid relative to non-cancer nucleic acid, designing primers that amplify at least one of the one or more structural variants in the cancer nucleic acid but lack a defined amplifiable target in the non-cancer nucleic acid, amplifying a test sample with the primers, and analyzing the amplification product for the presence of amplicons to thereby detect cancer nucleic acid in the test sample.

A method for denaturing a nucleic acid, comprising the following steps: - Providing (31) a solution (21) of the nucleic acid, - Denaturing (33) the nucleic acid by adding at least one base (23) to the solution (21), and - Adjusting (34) the pH of the solution to a value of less than 7 by adding at least one acid (24) to the solution (21), wherein the acid has a pKa value in the range of 1.0 to 5.0.

The invention relates to the technical field of kits, in particular to an oral cavity swab nucleic acid protection liquid and an extraction kit.The oral cavity swab nucleic acid protection liquid is composed of, by weight, 3.5-4.5% of anhydrous sodium acetate, 5-10% of polyethylene glycol, 5-10% of ethylenediaminetetraacetic acid and 5-10% of Tris hydrochloric acid, and the specific content is as follows: the anhydrous sodium acetate is 3.5-4.5%; 6%-8% of ethylenediamine tetraacetic acid; 0.8%-1.2% of Tris hydrochloric acid; 0.8%-1.2% of polyethylene glycol; the nucleic acid extraction method based on the paramagnetic particle method extraction kit is simple and convenient to operate, does not contain toxic reagents such as phenol chloroform and the like, can extract a plurality of samples at one time, realizes rapid diagnosis, simplifies experimental operation steps to the greatest extent, and ensures the safety of experimenters; the kit can meet the requirements of simplicity and convenience in operation, high sample flux and good nucleic acid extraction quality.

Methods and compositions for analyzing Tandem Repeats and single nucleotide polymorphisms use unlabeled, allele-specific PCR primers, a quenched fluorescent probe, and blocking nucleic acids which prevent amplification of specific numbers of tandem repeat units.

Methods and compositions for analyzing Tandem Repeats and single nucleotide polymorphisms use unlabeled, allele-specific PCR primers, a quenched fluorescent probe, and blocking nucleic acids which prevent amplification of specific numbers of tandem repeat units.

Methods and compositions for processing a target nucleic acid sequence are provided herein. The methods and compositions provided herein include a guide complex for recruiting an enzyme that can introduce a cleavage on the target nucleic acid sequence and a cleavage on the guide complex. The processed target nucleic acid sequence can be used in further applications, such as nucleic acid amplification (e.g., isothermal amplification).

The invention provides a host nucleic acid removal method for high-throughput sequencing, and belongs to the field of pathogenic microorganism detection. By limiting the types and use concentrations of reagents, host nucleic acid substances are ensured to be fully removed. In a high host background sample, the method is suitable for tissues and blood, background host nucleic acid can be effectively reduced, and the detection rate and the detection quantity of pathogenic microorganism gene sequences are improved.

Methods, compositions, and systems for identifying autoimmune disease subject response to an immunosuppressant drug are described herein.

Methods for strand-displacement amplification of a target nucleic acid have been developed. Compositions for use according to the methods are also provided. The methods typically include steps of removing, hybridizing and extending a selectively removable or digestible primer with a strand-displacing DNA polymerase once or more than once to provide a multiplicity of copies of the target nucleic acid. Methods for strand-displacement amplification of single or double-stranded target DNA molecules are provided. In some forms, when the methods include amplification of a double-stranded nucleic acid, the methods employ one or more adapter handles that perform the function of providing a removable region on a single strand of the ds target. Compositions and kits of oligonucleotide primers and double-stranded nucleic acid adapters including selectively removable regions are also provided for use in the described methods.

Methods and compositions for method of generating a population of captured target nucleic acids are provided. Exemplary methods can include contacting the plurality of oligonucleotides individually linked to a solid support with a sample comprising target nucleic acids having 3' ends and 5' ends, wherein target nucleic acids anneal to some of the free 3' ends of the oligonucleotides, and wherein there is an excess of oligonucleotides such that at least some oligonucleotides remain with free 3' ends; and then extending the target nucleic acid 3' end with a polymerase using the oligonucleotide as a template to form double-stranded portions that comprise a restriction enzyme recognition sequence; and then cleaving the restriction enzyme recognition sequence with a restriction enzyme to form released target nucleic acids having a single-stranded 5' end and a double-stranded 3' end and leaving oligonucleotides remain with free 3' ends uncleaved from the solid support; and optionally then separating the solid support and uncleaved oligonucleotides from the released target nucleic acids to form a solution of target nucleic acids.

The invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein / antibody based therapeutics.

The present application provides a method for preparing a TURNON signal amplification electrode and a method for detecting nucleic acids. The method uses chitosan, catechol, and nanomaterials (gold nanoparticles (Au-NP), nitrogen-doped carbon nanotubes (N-CNT)) to construct a three-dimensional porous membrane on the electrode surface. When miRNA-141 hybridizes with the probe on the membrane, ferrocene (Fc) will be introduced to the electrode surface, and then a 3D porous membrane containing Fc, ruthenium ions (Ru) will be formed. 3+ ), catechol and electrode pseudocapacitive system. Fc and Ru consumed in the electrode reaction 3+ It quickly returns to its original valence state on the catechol / quinone surface and re-enters the electrode reaction. The "one-to-many" relationship between the target miRNA and the signaling molecule Fc contributes to enhanced sensor sensitivity. The pseudocapacitive system improves the signal intensity and stability of Fc, thereby enhancing the sensitivity and stability of the sensor in detecting miRNA-141.

Methods and compositions for barcoding a target sequence and analysing a single cell are provided. An in situ amplification of a single barcode molecule based on polymerase / nicking cycles allow the generation of a large concentration of barcoded molecules in the same reactor wherein the single cell is subjected to analysis. The large concentration of barcoded molecules may be subsequently used for barcoding a target sequence that originates from the single cell

Methods and systems provided herein address current limitations of bisulfite-based methylation sequencing by improving the quality and accuracy of nucleic acid methylation sequencing and uses thereof for detection of disease. Methods that include minimally-destructive conversion methods for methylation sequencing as well as specialized UMI adapters provide for improved quality of sequencing libraries and sequencing information. Greater accuracy and more complete methylation-state information permits higher quality feature generation for use in machine learning models and classifier generation.

Methods, systems, and devices are provided for identifying and selectively amplifying correctly assembled nucleic acids comprising a sequence of interest from an assembled nucleic acid mixture. In some aspects, the invention uses resolution-merge enzymatic DNA synthesis to add bead-specific index sequences to clonal amplified assembled nucleic acids that bind beads. High throughput sequencing is used to identify beads comprising correctly assembled sequence perfect nucleic acids. The correct assembly nucleic acid may be selectively amplified using a primer comprising a sequence complementary to a bead-specific index sequence associated with the correct assembly nucleic acid.

Methods of producing RNA molecules in an in vitro transcription reaction are described. Also described are methods of producing mRNA molecules from a cyclic double-stranded DNA template using an in vitro transcription reaction system, wherein the in vitro transcription reaction system lacks a polyamine. An in vitro transcription reaction system comprising enzymatic 5'capping and oligomeric (dT) purification is also described.

Methods and reagents for blocking non-specific interactions with nucleic acids are disclosed. In particular, the invention relates to multi-valent blockers comprising multiple negatively charged polymers or materials attached to a common scaffold and their use in blocking non-specific interactions with nucleic acids.